Rasheed HA, Hussien NR, Al-Naimi MS, Al-Kuraishy HM, Al-Gareeb AI. Fenofibrate and Crataegus oxyacantha is an effectual combo for mixed dyslipidemia. Biomed Biotechnol Res J. 2020;4(3):259. https://doi.org/10.4103/bbrj.bbrj_26_20.

Article  Google Scholar 

Goncalves MD, Hwang SK, Pauli C, Murphy CJ, Cheng Z, Hopkins BD, et al. Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proc Natl Acad Sci USA. 2018;115(4):E743–52. https://doi.org/10.1073/pnas.1714703115.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Jung JY, Choi Y, Suh CH, Yoon D, Kim HA. Effect of fenofibrate on uric acid level in patients with gout. SciRep. 2018;8(1):16767. https://doi.org/10.1038/s41598-018-35175-z.

CAS  Article  Google Scholar 

FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61. https://doi.org/10.1016/S0140-6736(05)67667-2.

CAS  Article  Google Scholar 

Fischer J, Ganellin CR. Analogue-based drug discovery. Chem Int—Newsmag IUPAC. 2010;32(4):12–5.

Google Scholar 

Rabasa-Lhoret R, Rasamisoa M, Avignon A, Monnier L. Rare side-effects of fenofibrate. Diabetes Metab. 2001;27(1):66–8.

CAS  PubMed  Google Scholar 

Tsimihodimos V, Miltiadous G, Daskalopoulou SS, Mikhailidis DP, Elisaf MS. Fenofibrate: metabolic and pleiotropic effects. CurrVascPharmacol. 2005;3(1):87–98. https://doi.org/10.2174/1570161052773942.

CAS  Article  Google Scholar 

Sehgal N, Kumawat KL, Basu A, Ravindranath V. Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection. PLOSONE. 2012;7(4): e35427. https://doi.org/10.1371/journal.pone.0035427.

CAS  Article  Google Scholar 

Alleva LM, Budd AC, Clark IA. Minimising influenza disease with fibrates. Int J InfectDis. 2008;12: e176. https://doi.org/10.1016/j.ijid.2008.05.440.

Article  Google Scholar 

Badiou S, Merle De Boever CM, Dupuy AM, Baillat V, Cristol JP, Reynes J. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis. 2004;172(2):273–9. https://doi.org/10.1016/j.atherosclerosis.2003.10.006.

CAS  Article  PubMed  Google Scholar 

Huang W, Chen L, Zhang B, Park M, Toborek M. PPAR agonist-mediated protection against HIV Tat-induced cerebrovascular toxicity is enhanced in MMP-9-deficient mice. J Cereb Blood Flow Metab. 2014;34(4):646–53. https://doi.org/10.1038/jcbfm.2013.240.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Huang W, Rha GB, Han MJ, Eum SY, András IE, Zhong Y, et al. PPARα and PPARγ effectively protect against HIV-induced inflammatory responses in brain endothelial cells. J Neurochem. 2008;107(2):497–509. https://doi.org/10.1111/j.1471-4159.2008.05626.x.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Glitscher M, Martín DH, Woytinek K, Schmidt B, Tabari D, Scholl C, et al. Targeting cholesterol metabolism as efficient antiviral strategy against the hepatitis E virus. Cell MolGastroenterol Hepatol. 2021;12(1):159–80. https://doi.org/10.1016/j.jcmgh.2021.02.002.

CAS  Article  Google Scholar 

Zhang Y, Wang Z, Chen H, Chen Z, Tian Y. Antioxidants: potential antiviral agents for Japanese encephalitis virus infection. IntJ InfectDis. 2014;24:30–6. https://doi.org/10.1016/j.ijid.2014.02.011.

CAS  Article  Google Scholar 

Tao L, Lowe A, Wang G, Dozmorov I, Chang T, Yan N, Reese TA. Metabolic control of viral infection through PPAR-α regulation of STING signaling. BioRxiv. 2019;13:17.

Google Scholar 

Sychev ZE, Hu A, DiMaio TA, Gitter A, Camp ND, Noble WS, et al. Integrated systems biology analysis of KSHV latent infection reveals viral induction and reliance on peroxisome mediated lipid metabolism. PLOSPathog. 2017;13(3): e1006256. https://doi.org/10.1371/journal.ppat.1006256.

CAS  Article  Google Scholar 

Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma. 2007;24(7):1119–31. https://doi.org/10.1089/neu.2006.0216.

Article  PubMed  Google Scholar 

Undas A, Celinska-Löwenhoff M, Domagala TB, Iwaniec T, Dropinski J, Löwenhoff T, Szczeklik A. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost. 2005;94(1):193–9. https://doi.org/10.1160/TH05-01-0067.

CAS  Article  PubMed  Google Scholar 

Rosenson RS. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Obesity. 2009;17(3):504–9. https://doi.org/10.1038/oby.2008.530.

CAS  Article  PubMed  Google Scholar 

Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators. J BiolChem. 2000;275(47):36703–7. https://doi.org/10.1074/jbc.M004045200.

CAS  Article  Google Scholar 

Chen N, Jiang K, Yan GG. Effect of fenofibrate on diabetic retinopathy in rats via SIRT1/NF-κB signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(19):8630–6. https://doi.org/10.26355/eurrev_201910_19180.

CAS  Article  PubMed  Google Scholar 

Koh KK, Han SH, Quon MJ, Yeal Ahn JY, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care. 2005;28(6):1419–24. https://doi.org/10.2337/diacare.28.6.1419.

CAS  Article  PubMed  Google Scholar 

Rada MJ, Donato M, Penas FN, Alba Soto CD, Cevey ÁC, Pieralisi AV, et al. IL-10-dependent and-independent mechanisms are involved in the cardiac pathology modulation mediated by fenofibrate in an experimental model of Chagas heart disease. Front Immunol. 2020;11:2429.

Article  Google Scholar 

Lee JW, Bajwa PJ, Carson MJ, Jeske DR, Cong Y, Elson CO, et al. Fenofibrate represses interleukin-17 and interferon-γ expression and improves colitis in interleukin-10–deficient mice. Gastroenterology. 2007;133(1):108–23. https://doi.org/10.1053/j.gastro.2007.03.113.

CAS  Article  PubMed  Google Scholar 

Wahba MG, Messiha BA, Abo-Saif AA. Protective effects of fenofibrate and resveratrol in an aggressive model of rheumatoid arthritis in rats. PharmBiol. 2016;54(9):1705–15. https://doi.org/10.3109/13880209.2015.1125931.

CAS  Article  Google Scholar 

Shirinsky IV, Shirinsky VS. Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: a pilot study. RheumatolInt. 2014;34(5):613–6. https://doi.org/10.1007/s00296-013-2766-4.

CAS  Article  Google Scholar 

Chistyakov DV, Astakhova AA, Goriainov SV, Sergeeva MG. Comparison of PPAR ligands as modulators of resolution of inflammation, via their influence on cytokines and oxylipins release in astrocytes. IntJ MolSci. 2020;21(24):9577. https://doi.org/10.3390/ijms21249577.

CAS  Article  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Alzahrani KJ, Alexiou A, Batiha GE. Niclosamide for Covid-19: bridging the gap. MolBiolRep. 2021;48(12):8195–202. https://doi.org/10.1007/s11033-021-06770-7.

CAS  Article  Google Scholar 

Onohuean H, Al-Kuraishy HM, Al-Gareeb AI, Qusti S, Alshammari EM, Batiha GE. Covid-19 and development of heart failure: mystery and truth. Naunyn-SchmiedebergsArch Pharmacol. 2021;394(10):2013–21. https://doi.org/10.1007/s00210-021-02147-6.

CAS  Article  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Alkazmi L, Alexiou A, Batiha GE. Levamisole therapy in COVID-19. Viral Immunol. 2021;34(10):722–5. https://doi.org/10.1089/vim.2021.0042.

CAS  Article  PubMed  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Qusti S, Alshammari EM, Gyebi GA, Batiha GE. Covid-19-induced dysautonomia: a menace of sympathetic storm. ASN Neuro. 2021;13:17590914211057636. https://doi.org/10.1177/17590914211057635.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Qusty N, Cruz-Martins N, El-Saber Batiha GE. Sequential doxycycline and colchicine combination therapy in Covid-19: the salutary effects. PulmPharmacol Ther. 2021;67: 102008. https://doi.org/10.1016/j.pupt.2021.102008.

CAS  Article  Google Scholar 

Al-Kuraishy HM, Al-Gareeb AI, Alqarni M, Cruz-Martins N, El-Saber BG. Pleiotropic effects of tetracyclines in the management of COVID-19: emerging perspectives. Front Pharmacol. 2021;12: 642822. https://doi.org/10.3389/fphar.2021.642822.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Batiha GE. Cyclosporine attenuates Covid-19: ensnare or victory. Ann Clin Med Case Rep. 2021;7(4):1–8.

Google Scholar 

Hassan T. Fenofibrate, a drug for COVID-19? All we need to know. J Rawalpindi Med Coll. 2021;25(4):441–2.

Article  Google Scholar 

Gupta RK, Nwachuku EL, Zusman BE, Jha RM, Puccio AM. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium. PLOSONE. 2021;16(9): e0257784. https://doi.org/10.1371/journal.pone.0257784.

CAS  Article  Google Scholar 

Yasmin F, Zeeshan MH, Ullah I. The role of fenofibrate in the treatment of COVID-19. Ann Med Surg. 2022;74: 102974. https://doi.org/10.1016/j.amsu.2021.102974.

Article  Google Scholar 

Buschard K. Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. MedHypotheses. 2020;143: 110127. https://doi.org/10.1016/j.mehy.2020.110127.

CAS  Article  Google Scholar 

Guo R, Hu X, Yamada Y, Harada M, Nakajima T, Kashihara T, et al. Effects of hypertension and antihypertensive treatments on sulfatide levels in serum and its metabolism. HypertensRes. 2019;42(5):598–609. https://doi.org/10.1038/s41440-018-0160-z.

CAS  Article  Google Scholar 

Blomqvist M, Kaas A, Månsson JE, Formby B, Rynmark BM, Buschard K, Fredman P. Developmental expression of the type I diabetes related antigen sulfatide and sulfated lactosylceramide in mammalian pancreas. J Cell Biochem. 2003;89(2):301–10. https://doi.org/10.1002/jcb.10513.

CAS  Article  PubMed  Google Scholar